When a Fed official openly talks about economic pain, higher unemployment and more rate hikes, markets listen. Some investors retreat. Others start hunting for businesses that might actually gain from higher-for-longer rates. This article focuses on that second camp. You will see three U.S. life insurance and annuity providers from our screener that look closely tied to this new rate debate, and why their exposure to the latest Fed signals matters to your portfolio thinking.
The three stocks below are a starting sample, and the full screen surfaced 10 more U.S. life insurers and annuity providers with equally detailed stories around higher-for-longer rates that are not covered here.
If you want to move beyond the shortlist and actively sort through the full set of ideas, head straight into the U.S. Life Insurers and Annuity Providers Leveraging Higher-for-Longer Interest Rates screener to identify, analyze, and focus on the higher conviction candidates for your own watchlist.
Overview: Aflac provides supplemental health and life insurance in the U.S. and Japan, using its insurance float to support a sizable investment portfolio.
Operations: Aflac generates about US$7.0b from Aflac U.S., US$8.9b from Aflac Japan, and US$1.2b from Corporate and Other activities.
Market Cap: US$58.3b
Aflac provides exposure to a large life and supplemental insurer that reinvests substantial float in fixed income assets. Maturing bonds may be replaced at higher yields in a higher-for-longer rate environment. Dividend income, recent earnings strength and disciplined investment positioning are all important considerations, depending on how one unseen pressure develops.
That unseen pressure is exactly what you need to stress test in the 3 key rewards and 2 important warning signs (1 is major!) before deciding how Aflac fits into your higher-rate play.
Overview: Kansas City Life Insurance offers traditional individual and group life policies and final expense coverage, giving investors pure-play exposure to life insurance earnings tied to long-term investment yields.
Operations: Kansas City Life Insurance generates about US$326 million from Individual Insurance, US$92 million from Old American, and US$71 million from Group Insurance, almost entirely in the United States.
Market Cap: US$352 million
Kansas City Life Insurance sits firmly in the higher-for-longer sweet spot. Traditional life policies, long-duration liabilities and a US$352 million market value are directly related to the screener theme, while 2026 results show a move back into profit and an affirmed dividend. The key issue is how much of that rate-driven spread uplift ultimately remains if one unresolved funding pressure tightens.
If that funding squeeze is what you are trying to size up next, go straight to the 2 key rewards and 3 important warning signs (2 are major!) for details on how Kansas City Life Insurance could respond.
Overview: Pekin Life Insurance provides life, annuity, accident and health coverage, plus related auto, home and business policies in the United States.
Operations: Pekin Life Insurance reports declining US$72 million life and health insurance revenue, all generated within the United States, underscoring its domestic focus.
Market Cap: US$201 million
Pekin Life Insurance links directly to the higher-for-longer theme through its life and annuity float. However, current profit margins are weak and ROE is only 0.3%. The stock is tiny, trades on thin volume and carries governance questions, so any uplift from richer long bond yields depends on how one unseen pressure plays out against that fragile base.
That hinge point is exactly why the 4 warning signs (3 are major!) could matter for Pekin Life Insurance, before any balance sheet strain starts masking long-term opportunity.
Fresh breakouts and early momentum often get caught by data first, not headlines. Screen under-the-radar ideas before the crowd, while it matters, and act now.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com